Yu Gu

Background: Short‑video platforms have become a primary source of health information in China, yet the quality and reliability of disease‑related content remain largely unregulated. Numerous cross‑sectional studies have revealed suboptimal quality, significant platform disparities, and the superiority of professional‑generated content. However, haematological malignancies, particularly leukaemia, have been conspicuously overlooked, and the mechanisms underlying these patterns, as well as the clinical impact of misinformation, remain underexplored. Leukaemia is the most common childhood malignancy in China, with an incidence of 42.33 per million in children aged 0–14 years, and its treatment encompasses chemotherapy, targeted therapy, immunotherapy, radiotherapy, and stem cell transplantation. This study aimed to assess the quality and credibility of leukaemia‑related short videos on TikTok and Bilibili. Methods: A cross‑sectional content analysis was conducted in November 2025. Using the Chinese search term “leukaemia,” 232 videos were retrieved from TikTok ( n = 123) and Bilibili ( n = 109). Two independent reviewers evaluated video quality and reliability using the GQS and mDISCERN. Content themes were categorised across seven dimensions, and engagement metrics were recorded. Results: Overall quality and reliability were suboptimal (median GQS and mDISCERN: 2.00, IQR: 2.00–3.00). “Symptoms” was the most prevalent topic (27.13%), while “epidemiology” (4.33%) and “prevention” (6.06%) were severely underrepresented. Bilibili videos had significantly higher GQS scores than TikTok ( p < 0.05), whereas TikTok demonstrated substantially higher user engagement. Specialist‑generated content received the highest GQS scores ( p < 0.05), whereas mDISCERN scores did not differ significantly across uploader groups. No significant correlation was found between engagement and quality. Conclusions: Leukaemia‑related short‑video content in China shows suboptimal quality and reliability, with critical gaps in epidemiology, prevention, and diagnosis. To address these deficiencies, we propose actionable measures: professionals should systematically cover essential domains; platforms should implement creator verification, algorithmic weighting, and triage review; warning labels for misleading content; and hospital‑run official accounts for quality‑assured education. These findings underscore the need for enhanced content governance and professional engagement in digital health communication.

Immune checkpoint inhibitors (ICIs) have revolutionized anti-tumor therapy, yet their use is increasingly complicated by immune-related adverse events (irAEs). We present a rare case in which sequential administration of two PD−1 inhibitors (ICIs), Camrelizumab and Sintilimab, in combination with conventional chemotherapy led to ICI-related systemic sclerosis (ICI-SSc) with early-stage interstitial lung disease (ILD) and autoimmune thyroiditis (AIT). The clinical presentation also suggested a possible scleroderma overlap syndrome. The underlying pathology is likely linked to widespread immune activation following PD−1 pathway blockade. Early identification of ICI-SSc is crucial. Once the diagnosis is confirmed, the suspected drug should be discontinued immediately, and a personalized treatment plan should be initiated, ideally with consideration of the safety profile of steroid-based regimens. Furthermore, our findings raise important considerations regarding pharmacovigilance in the context of sequential ICIs use.

Background: The identification of reliable biomarkers for predicting disease recurrence and the survival of patients with cancer is of great importance. Numerous previous studies have revealed that the abnormal expression of the suppressor of cytokine signaling 3 (SOCS3) was associated with patient outcomes. However, these results were inconsistent. The aim of the present study was to assess the prognostic value of SOCS3 in patients with solid tumors.Methods: Studies focusing on the prognostic value of SOCS3 in solid tumors were searched for in the PubMed, Embase, Web of Science, and Scopus databases. We included studies that compared disease-free survival (DFS) and overall survival based on different levels of SOCS3. Other outcomes (e.g., Edmondson grading, tumor size, tumor vascular invasion, lymph node invasion, and distant metastasis) were also considered. The hazard ratio (HR)/risk ratio (RR) and corresponding 95% CI were determined.Results: Twelve studies with 1,551 patients were included in this meta-analysis. The pooled analysis demonstrated that the higher expression of SOCS3 was significantly associated with better disease-free survival (HR:0.36, 95% CI:0.17–0.77, P < 0.001) and overall survival (HR:0.45, 95% CI:0.32–0.62, P < 0.001) compared with low expression. Moreover, SOCS3 expression was closely correlated with the Edmondson grading [odds ratio (OR):0.77, 95% CI:0.61–0.98, P = 0.033], vascular invasion (OR:0.63, 95% CI:0.52–0.78, P < 0.001), and distant metastasis (OR:0.73, 95% CI:0.51–1.03, P = 0.076). However, the levels of SOCS3 were not significantly associated with tumor size (OR:0.85, 95% CI:0.71–1.03, P = 0.090) and lymph node invasion (OR:0.73, 95% CI:0.51–1.03, P = 0.076).Conclusion: Increased SOCS3 expression in tumor mass was associated with better DFS and OS, suggesting it might be a novel and reliable biomarker for predicting the risk of cancer recurrence and mortality.